Navigation Links
Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin
Date:2/19/2008

ignated cethromycin as an orphan drug for the prophylactic treatment of inhalation anthrax post-exposure, but the drug is not yet approved for this or any other indication.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at http://www.advancedlifesciences.com.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our management's judgment regarding future events. The Company does not undertake any obligations to update any forward-looking statements whether as a result of new information, future events or otherwise. Our actual results could differ materially from those discussed herein due to several factors including the success and timing of our clinical trials and our ability to obtain and maintain regulatory approval and labeling of our product candidates; our plans to develop and commercialize our product candidates; the loss of key scientific or management personnel; the size and growth of potential markets for our product candidates and our ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of our estimates regarding expenses, future revenues and capital requirements; our ability to obtain financing on terms acceptable to us; our ability to obtain and mai
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
4. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
5. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
6. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
7. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
11. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... DUBLIN , Aug. 4, 2015 /PRNewswire/ ... announced the addition of Jain PharmaBiotech,s new ... Markets, and Companies" to their offering. ... transdermal drug delivery - an approach used ... therapeutic use as an alternative to oral,intravascular, ...
(Date:8/4/2015)... Concord Medical Services Holdings Limited ("Concord Medical", or the "Company") ... operator of the largest network of radiotherapy and diagnostic imaging ... will release its financial results for the second quarter of ... Management will hold a conference call to discuss the ... 18, 2015 (8:00 p.m. in Beijing / ...
(Date:8/4/2015)... , August 4, 2015 ... with market overview, trends, DRO analysis, market segmentation, ... competitive scenario and top competitor profiles in: ... Testing Market Development and Demand Forecast to 2020  ... Explore full reports with detailed TOC ...
Breaking Medicine Technology:Transdermal Drug Delivery Report 2015-2024 - Technologies, Markets, and Companies Analysis 2Concord Medical to Report Second Quarter 2015 Financial Results on August 17, 2015 2Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 2Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 3Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 4Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 5
... The American College of Medical Genetics (ACMG) ... decision to make Critical Congenital Cyanotic Heart Disease (CCCHD) ... Secretary,s Advisory Committee on Heritable Disorders in Newborns and ... MD, FACMG had made the recommendations to Secretary Kathleen ...
... 2011 Visionsense Corp announces an unique milestone this ... 500th neurosurgical procedure with the VSii system. ... Vice-Chairman, Dept of Neurosurgery at Emory University and Professor ... of a pituitary adenoma in the morning of September ...
Cached Medicine Technology:American College of Medical Genetics Applauds HHS Secretary's Decision to Expand Newborn Screening to Include Critical Congenital Heart Disease 2
(Date:8/4/2015)... ... August 04, 2015 , ... School is almost back in session. Parents and ... for the back-to-school scramble. Dublin, OH family dentist , Dr. Cheung (of BrightSmile ... annual dental checkup. In fact, the dentist recently updated the practice’s surgical suite to ...
(Date:8/4/2015)... ... ... Many men are confused about the safety of testosterone replacement therapy. In ... voice of authority for men seeking accurate information about testosterone. , Renew Man™ ... in the safe and effective treatment of low testosterone. In recent years, the experts ...
(Date:8/4/2015)... ... August 04, 2015 , ... Buckeye Health Plan is reminding ... immunizations are covered for members under the Healthchek program . , “Many ... with their immunizations may not be allowed to attend when school begins in ...
(Date:8/4/2015)... ... August 04, 2015 , ... SanusEO, ... Bruce McCalley joins its executive leadership team as Senior Vice President of Sales ... technology companies and expanding global markets with a special emphasis on the healthcare ...
(Date:8/4/2015)... ... August 04, 2015 , ... T.E.N., an information technology ... participating in The ISE® Lions’ Den and Jungle Lounge 2015, which will be held ... Vegas. , During the event, eight emerging security vendors, known as “Gazelles,” will go ...
Breaking Medicine News(10 mins):Health News:Dublin OH Family Dentist Offers Complimentary Back-to-School Cleanings, a Revamped Suite, and In-House Esthetician to Accommodate All Patients 2Health News:Dublin OH Family Dentist Offers Complimentary Back-to-School Cleanings, a Revamped Suite, and In-House Esthetician to Accommodate All Patients 3Health News:Dublin OH Family Dentist Offers Complimentary Back-to-School Cleanings, a Revamped Suite, and In-House Esthetician to Accommodate All Patients 4Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:Buckeye Health Plan Reminds Parents to Keep Immunizations In Mind As School Year Kicks Off 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 2Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 3Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 4
... release is available in Spanish . U.S. ... laboratory rats fed blueberries or other foods of interest may ... has paved the way to follow-up experiments, Rosalia C. M. ... Rock, Ark., has determined that several indicators of rat mammary ...
... more common disease striking overweight, younger women is the ... where an osteopathic physician is testing the effectiveness of ... Idiopathic intracranial hypertension, known as IIH or pseudo-tumor cerebri, ... the brain, specifically in the absence of a tumor. ...
... year, 10,000 pregnant women and up to 200,000 newborn babies ... globe have for years been looking in vain for a ... have found the biochemically weakness of the lethal malaria parasite, ... related malaria. The malaria parasite travels via the spit ...
... with colon cancer that had spread to distant sites found ... drug regimen that was not recommended. Those patients were exposed ... for the drugsof more than $2 million. The study, ... the American Society for Clinical Oncology,s annual meeting in Chicago, ...
... Blocking two tiny molecules of RNA a chemical ... of blood vessels that occurs in degenerative eye disorders, UT ... in the Proceedings of the National Academy of Sciences ... (AMD), a vascular eye disorder that affects nearly 2 million ...
... (HealthDay News) -- One of the first and largest national ... that those who identify as gay, lesbian or bisexual are ... The study was conducted by the U.S. Centers for ... 2001-2009. It found that rates of smoking, drinking or other ...
Cached Medicine News:Health News:Mammary gland development of blueberry-fed lab animals studied 2Health News:Researcher tests drug's impact on neurological disease affecting women 2Health News:Researchers discover biochemical weakness of malaria parasite -- vaccine to be developed 2Health News:Many patients with advanced cancers get treatments that won't help 2Health News:Many patients with advanced cancers get treatments that won't help 3Health News:Researchers find that inhibiting microRNAs may help prevent degenerative eye disorders 2Health News:More Risky Behaviors Among Gay, Bisexual High School Students: CDC 2
... the only dura material versatile enough for ... closure, and in cases where biological fixation ... in cases requiring an immediate watertight seal ... biological fixation and sealing are key factors ...
The Bovie IDS Series are the latest electrosurgical generators with fully digital implementation....
Aaron 1250 is a multipurpose electrosurgical generator with monopolar and bi-polar functions....
Bipolar foot activated forceps....
Medicine Products: